Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3-hydroxybutyrate (BHB) is a naturally occurring small molecule and the major circulating ketone body in humans. It is produced in the liver from fatty acids during periods of low carbohydrate intake or fasting and serves as an alternative energy source for the brain and other tissues when glucose is scarce. BHB has roles as a human metabolite and energy substrate during ketosis. It has been studied for potential therapeutic effects in neurological conditions such as epilepsy, multiple sclerosis, stroke, Parkinson's disease, Alzheimer's disease, Huntington's disease, depressive disorder, and schizophrenia[6]. Oral administration of BHB has shown partial efficacy on cognitive function and broad efficacy on mood parameters in healthy adults[8]. Mechanistically it acts primarily by serving as an alternative metabolic fuel; it may also have signaling functions affecting gene expression and inflammation pathways[6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-hydroxybutyrate.